PH12020551178A1 - Novel small molecule drug conjugates of gemcitabine derivatives - Google Patents

Novel small molecule drug conjugates of gemcitabine derivatives

Info

Publication number
PH12020551178A1
PH12020551178A1 PH12020551178A PH12020551178A PH12020551178A1 PH 12020551178 A1 PH12020551178 A1 PH 12020551178A1 PH 12020551178 A PH12020551178 A PH 12020551178A PH 12020551178 A PH12020551178 A PH 12020551178A PH 12020551178 A1 PH12020551178 A1 PH 12020551178A1
Authority
PH
Philippines
Prior art keywords
small molecule
drug conjugates
molecule drug
novel small
gemcitabine derivatives
Prior art date
Application number
PH12020551178A
Other languages
English (en)
Inventor
Steven Albert Everett
Craig Alan Coburn
Original Assignee
Maverix Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maverix Oncology Inc filed Critical Maverix Oncology Inc
Publication of PH12020551178A1 publication Critical patent/PH12020551178A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545Heterocyclic compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06Pyrimidine radicals
    • C07H19/10Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/0004Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/902Oxidoreductases (1.)
    • G01N2333/90245Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/24Post-translational modifications [PTMs] in chemical analysis of biological material hydroxylation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
PH12020551178A 2018-02-02 2020-08-03 Novel small molecule drug conjugates of gemcitabine derivatives PH12020551178A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862625779P 2018-02-02 2018-02-02
PCT/US2019/016477 WO2019152911A1 (en) 2018-02-02 2019-02-04 Novel small molecule drug conjugates of gemcitabine derivatives

Publications (1)

Publication Number Publication Date
PH12020551178A1 true PH12020551178A1 (en) 2021-06-07

Family

ID=65494546

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12020551178A PH12020551178A1 (en) 2018-02-02 2020-08-03 Novel small molecule drug conjugates of gemcitabine derivatives

Country Status (13)

Country Link
US (1) US20210380626A1 (https=)
EP (1) EP3746133A1 (https=)
JP (2) JP2021512951A (https=)
KR (1) KR20200118828A (https=)
CN (1) CN112135635A (https=)
AU (1) AU2019216514A1 (https=)
BR (1) BR112020015747A2 (https=)
CA (1) CA3090272A1 (https=)
EA (1) EA202091857A1 (https=)
IL (1) IL276442A (https=)
PH (1) PH12020551178A1 (https=)
SG (1) SG11202007381YA (https=)
WO (1) WO2019152911A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20210367A1 (es) * 2018-02-02 2021-02-26 Maverix Oncology Inc Conjugados de farmacos de molecula pequena de monofosfato de gemcitabina
CN114349816B (zh) * 2021-11-30 2024-08-30 潍坊博创国际生物医药研究院 一种基于氨肽酶n/cd13的小分子偶联分子及其制备方法和应用
WO2026009986A1 (ja) * 2024-07-05 2026-01-08 学校法人東京理科大学 化合物の製造方法及び化合物
WO2026009987A1 (ja) * 2024-07-05 2026-01-08 学校法人東京理科大学 化合物の製造方法、化合物、及びヌクレオチドプロドラッグ前駆体
CN119708099B (zh) * 2024-12-23 2025-10-24 中国药科大学 吉西他滨前药及其医药用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2531599A (en) 1998-02-12 1999-08-30 De Montfort University Hydroxylation activated drug release
US7148226B2 (en) 2003-02-21 2006-12-12 Agouron Pharmaceuticals, Inc. Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
GB0317009D0 (en) * 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
GB0907551D0 (en) * 2009-05-01 2009-06-10 Univ Dundee Treatment or prophylaxis of proliferative conditions
JP6212831B2 (ja) * 2013-12-04 2017-10-18 杭州源昶医薬科技有限公司 ゲムシタビン誘導体、該誘導体を含む組成物及び該誘導体の製薬用途
WO2015134334A1 (en) * 2014-03-03 2015-09-11 Suo Zucai Gemcitabine analogs
CN105001291B (zh) * 2014-04-15 2018-12-04 上海知萌生物医药科技有限公司 吉西他滨化学传递前药及其制备方法和应用
US20180044368A1 (en) * 2015-02-25 2018-02-15 Ligand Pharmaceuticals, Inc. Gemcitabine derivatives

Also Published As

Publication number Publication date
KR20200118828A (ko) 2020-10-16
US20210380626A1 (en) 2021-12-09
SG11202007381YA (en) 2020-08-28
EP3746133A1 (en) 2020-12-09
EA202091857A1 (ru) 2020-12-04
AU2019216514A1 (en) 2020-09-24
JP2024073414A (ja) 2024-05-29
JP2021512951A (ja) 2021-05-20
BR112020015747A2 (pt) 2020-12-08
IL276442A (en) 2020-09-30
CN112135635A (zh) 2020-12-25
CA3090272A1 (en) 2019-08-08
WO2019152911A1 (en) 2019-08-08

Similar Documents

Publication Publication Date Title
PH12020551178A1 (en) Novel small molecule drug conjugates of gemcitabine derivatives
JOP20220155A1 (ar) مشتقات البيرازول مفيدة كعوامل مضادة للسرطان
PH12013501340A1 (en) Bicyclo[3.2.1]octyl amide derivatives and uses of same
MY192084A (en) Pyrazolo-heteroaryl derivative, preparation method and medical use thereof
SA521422143B1 (ar) 15-pgdh مثبط
CY1119261T1 (el) Παραγωγα θειαζολιου
MY151986A (en) Adamantyl diamide derivatives and uses of same
UY30310A1 (es) Derivados 2-azetidinona, sales, solvatos, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones
MX2010003155A (es) Derivados de ciclopropil aril amida y uso de los mismos.
WO2012030685A3 (en) Indazole derivatives useful as erk inhibitors
MX2010006799A (es) Benzofuropirimidinonas como inhibidores de la proteina cinasa.
HRP20090077B1 (hr) Modulatori farmakokinetičkih svojstava terapeutika
MX2009008540A (es) Inhibidores de virus de hepatitis c macrociclicos sustituidos con pirimidina.
GEAP202215088A (en) Magl inhibitors
MX2009008541A (es) Fenilcarbamatos macrociclicos que inhiben el virus de hepatitis c.
EA200900282A1 (ru) Применение полиолов для получения устойчивых полиморфных форм рифаксимина
TW200613243A (en) Novel compounds
WO2009066315A3 (en) Sustained release compositions of trimetazidine and process for preparation thereof
EP4364802A3 (en) Compositions comprising methylphenidate-prodrugs, processes of making and using the same
PH12021550439A1 (en) O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors
MX390044B (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia.
WO2009032843A3 (en) Deuterated ethambutols and their use
ZA202203107B (en) Azaindole carboxamide compounds for the treatment of mycobacterial infections
PH12022553516A1 (en) Novel pyrazole derivatives
HK1200392A1 (en) Acetaminophen conjugates, compositions and methods of use thereof